株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全身性紅斑性狼瘡 (SLE):パイプライン製品の分析

Systemic Lupus Erythematosus - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 264101
出版日 ページ情報 英文 409 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
全身性紅斑性狼瘡 (SLE):パイプライン製品の分析 Systemic Lupus Erythematosus - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 409 Pages
概要

全身性紅斑性狼瘡 (SLE) は、慢性的な炎症性疾患の原因となる自己免疫疾患です。SLEが原因の炎症によって、皮膚や関節、腎臓、脳などの様々な器官が影響を受けます。様々な要因が遺伝、環境、性、ホルモンなどの疾患と関係しています。症侯は様々で、時間とともに変化しますが、一般的なものとして重度の疲労感、関節の痛みや腫れ、頭痛、蝶形紅斑と呼ばれる頬や鼻の発疹、抜け毛、貧血などがあります。

当レポートでは、全身性紅斑性狼瘡 (SLE) の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

全身性紅斑性狼瘡の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9327IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 26, 28, 1, 44, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Systemic Lupus Erythematosus - Overview
  • Systemic Lupus Erythematosus - Therapeutics Development
  • Systemic Lupus Erythematosus - Therapeutics Assessment
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
  • Systemic Lupus Erythematosus - Drug Profiles
  • Systemic Lupus Erythematosus - Dormant Projects
  • Systemic Lupus Erythematosus - Discontinued Products
  • Systemic Lupus Erythematosus - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Kadmon Corp LLC, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Seattle Genetics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Shire Plc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by TxCell SA, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by UCB SA, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H1 2017
  • Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Systemic Lupus Erythematosus - Discontinued Products, H1 2017
  • Systemic Lupus Erythematosus - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top